Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
23,9 NOK | +1,70 % | 0,00 % | +2,58 % |
24.04. | Vistin Pharma ASA meldet Ergebnis für das erste Quartal bis zum 31. März 2024 | CI |
24.04. | Transcript : Vistin Pharma ASA, Q1 2024 Earnings Call, Apr 24, 2024 |
Kurzporträt
Mitarbeiterzahl: 78
Umsatz nach Geschäftsbereich
NOK in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Pharmaceuticals
100,0
%
| 288 | 100,0 % | 435 | 100,0 % | +51,35 % |
Umsatz je Region
NOK in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Europe
77,8
%
| 196 | 68,1 % | 339 | 77,8 % | +72,91 % |
Africa
15,1
%
| 37 | 13,0 % | 66 | 15,1 % | +75,29 % |
Asia
6,7
%
| 20 | 6,9 % | 29 | 6,7 % | +48,11 % |
North and South America
0,3
%
| 34 | 12,0 % | 2 | 0,3 % | -95,63 % |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Chief Executive Officer | - | 01.03.20 | |
Director of Finance/CFO | - | 02.03.20 | |
Eivind Egeli
CTO | Chief Tech/Sci/R&D Officer | - | 01.06.15 |
Vegard Heggem
PRN | Corporate Officer/Principal | - | 01.06.15 |
Sabrina Berge
PRN | Corporate Officer/Principal | - | 01.06.15 |
General Counsel | - | 01.03.15 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Chairman | 76 | 01.06.20 | |
Director/Board Member | 62 | 06.03.15 | |
Director/Board Member | 60 | - | |
Bettina Banoun
BRD | Director/Board Member | 52 | 08.05.18 |
Åse Musum
BRD | Director/Board Member | - | 01.06.15 |
Director/Board Member | - | 04.05.20 | |
Director/Board Member | - | 01.01.17 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 44 344 592 | 20 062 899 ( 45,24 %) | 0 | 45,24 % |
Unternehmenskontakt
Konzerngesellschaften
Name | Kategorie und Branche |
---|---|
Vistin Trading AS
Vistin Trading AS Finance/Rental/LeasingFinance Part of Vistin Pharma ASA, Vistin Trading AS offers trade in financial instruments and other investments. The private company is based in Oslo, Norway. |
Finance/Rental/Leasing
|
Vistin Pharma AS
Vistin Pharma AS Pharmaceuticals: MajorHealth Technology Part of Vistin Pharma ASA, Vistin Pharma is a leading European metformin producer supplying to international pharmaceutical companies. The private company is located in Norway. Metformin is a standard first-line treatment for type 2 diabetes. The Norwegian company believes in balancing business growth with environmental sustainability, social responsibility, and ethical business practices. |
Pharmaceuticals: Major
|
Sektor
Umsatz je Region
% 1. Jan. | Kap. | |
---|---|---|
+2,58 % | 95,97 Mio. | |
+19,62 % | 43,34 Mrd. | |
+20,44 % | 21,96 Mrd. | |
+10,86 % | 14,09 Mrd. | |
+13,07 % | 13,64 Mrd. | |
+37,46 % | 11,43 Mrd. | |
-8,59 % | 6,86 Mrd. | |
-0,05 % | 6,79 Mrd. | |
-8,87 % | 5,73 Mrd. | |
+8,46 % | 5,22 Mrd. |
- Börse
- Aktien
- A14TLR Aktie
- Unternehmen Vistin Pharma ASA